Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chronic Lymphocytic Leukemia
Alemtuzumab effective therapy for CLL with p53 mutations and deletions
August 6th, 2004
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. "The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group. "Thirty-six patients with fludarabine-refractory CLL were treated with alemtuzumab, 15 (42%) of whom had p53 mutations or deletions," researchers in the United States report. "Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%)...
Source: Genomics & Genetics Weekly (2004-08-06)
|
